Immunity for Health

IfH Symposium: Innovations in Antibody-Based Biologics

11 Jun 2026 | Landmark Building, UZ Brussels, Belgium

argenx

Biotech / Medtech / Start-up

Gent, Belgium
4 profile visits

About

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

HEALTH SECTOR

Human health

RESEARCH AND DEVELOPMENT

Preclinical researchBiomarker discoveryTranslational research

CLINICAL DEVELOPMENT AND TRIALS

Clinical trials

DATA MANAGEMENT AND ANALYTICS

Data management and analytics

INVESTMENT AND BUSINESS DEVELOPMENT

Business development and partnershipsCommunication & HR

PATIENT ENGAGEMENT AND ADVOCACY

Patient engagement

DIGITAL HEALTH AND TECHNOLOGY

Nanotechnology

THERAPEUTIC AREAS

ImmunologyAutoimmune disordersRare diseasesRespiratory diseasesAllergiesCardiovascular diseasesNeurodegenerative diseases

Representatives

Principle Scientist Discovery

argenx

Strategic Alliances

argenx

Scientist Discovery

argenx

Marketplace (2)

  • Partnership

    Immunology Innovation Program

    We are always on the look out to build strong partnerships with leading key opinion leaders in the field of auto-immunity to collaborate on new innovative therapies

    Author

    Strategic Alliances at argenx

    Ghent, Belgium

  • Expertise

    Antibody engineering

    Using our proprietary SIMPLE Antibody™ and Fc engineering platforms, argenx scientists design and optimize antibodies that engage and modulate the immune system, unlocking new therapeutic pathways in autoimmune and rare diseases.

    Author

    Strategic Alliances at argenx

    Ghent, Belgium